tradingkey.logo

STRATA Skin Sciences Inc

SSKN
1.070USD
+0.040+3.88%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
5.64MMarktkapitalisierung
VerlustKGV TTM

STRATA Skin Sciences Inc

1.070
+0.040+3.88%

mehr Informationen über STRATA Skin Sciences Inc Unternehmen

STRATA Skin Sciences, Inc. is a medical technology company in dermatology. The Company is engaged in developing, commercializing and marketing products for the treatment of dermatologic conditions. The Company operates through two segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment. The Company’s products include the XTRAC and Pharos excimer lasers and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its products also include the TheraClear Acne Therapy System utilized in the treatment of mild to moderate inflammatory, comedonal and pustular acne. The XTRAC and Pharos excimer laser technology emits highly concentrated ultraviolet (UV) light targeted primarily towards autoimmune dermatological skin disorders, such as psoriasis, vitiligo, atopic dermatitis, and eczema, among others. VTRAC is a UV light lamp system that works in much the same way as the XTRAC.

STRATA Skin Sciences Inc Informationen

BörsenkürzelSSKN
Name des UnternehmensStrata Skin Sciences Inc
IPO-datumOct 28, 2005
CEORafaeli (Dolev)
Anzahl der mitarbeiter106
WertpapierartOrdinary Share
GeschäftsjahresendeOct 28
Addresse5 Walnut Grove Drive, Suite 140
StadtHORSHAM
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl19044
Telefon12156193200
Websitehttps://www.strataskinsciences.com/
BörsenkürzelSSKN
IPO-datumOct 28, 2005
CEORafaeli (Dolev)

Führungskräfte von STRATA Skin Sciences Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Christina L. Allgeier, CPA
Ms. Christina L. Allgeier, CPA
Independent Director
Independent Director
--
--
Dr. Dolev Rafaeli
Dr. Dolev Rafaeli
President, Chief Executive Officer, Vice Chairman of the Board
President, Chief Executive Officer, Vice Chairman of the Board
--
-32960.00%
Dr. Uri Geiger
Dr. Uri Geiger
Chairman of the Board
Chairman of the Board
--
--
Mr. Shmuel (Samuel) Rubinstein
Mr. Shmuel (Samuel) Rubinstein
Independent Director
Independent Director
--
--
Mr. Shmuel Gov
Mr. Shmuel Gov
Chief Operating Officer
Chief Operating Officer
--
-4675.00%
Mr. John Gillings
Mr. John Gillings
Chief Accounting Officer
Chief Accounting Officer
--
--
Dr. Irit Yaniv
Dr. Irit Yaniv
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Christina L. Allgeier, CPA
Ms. Christina L. Allgeier, CPA
Independent Director
Independent Director
--
--
Dr. Dolev Rafaeli
Dr. Dolev Rafaeli
President, Chief Executive Officer, Vice Chairman of the Board
President, Chief Executive Officer, Vice Chairman of the Board
--
-32960.00%
Dr. Uri Geiger
Dr. Uri Geiger
Chairman of the Board
Chairman of the Board
--
--
Mr. Shmuel (Samuel) Rubinstein
Mr. Shmuel (Samuel) Rubinstein
Independent Director
Independent Director
--
--
Mr. Shmuel Gov
Mr. Shmuel Gov
Chief Operating Officer
Chief Operating Officer
--
-4675.00%
Mr. John Gillings
Mr. John Gillings
Chief Accounting Officer
Chief Accounting Officer
--
--

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6
Währung: USDAktualisiert: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach RegionUSD
Name
Umsatz
Anteil
United States (Country)
5.22M
75.31%
Other foreign
939.00K
13.55%
Foreign
470.00K
6.78%
Middle East
172.00K
2.48%
China
130.00K
1.88%
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Wed, Feb 4
Aktualisiert: Wed, Feb 4
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Accelmed Growth Partners Management Ltd
24.49%
22NW, LP
9.12%
Nantahala Capital Management, LLC
6.86%
Lincoln Alternative Strategies LLC
6.21%
Renaissance Technologies LLC
1.72%
Andere
51.60%
Aktionäre
Aktionäre
Anteil
Accelmed Growth Partners Management Ltd
24.49%
22NW, LP
9.12%
Nantahala Capital Management, LLC
6.86%
Lincoln Alternative Strategies LLC
6.21%
Renaissance Technologies LLC
1.72%
Andere
51.60%
Aktionärstypen
Aktionäre
Anteil
Private Equity
24.49%
Investment Advisor/Hedge Fund
9.60%
Hedge Fund
8.62%
Corporation
6.21%
Investment Advisor
0.85%
Individual Investor
0.18%
Andere
50.06%

Institutionelle Beteiligung

Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
39
2.56M
43.55%
-107.46K
2025Q3
40
2.60M
49.33%
-171.52K
2025Q2
42
2.84M
68.01%
+22.22K
2025Q1
49
2.92M
70.24%
+3.78K
2024Q4
50
2.78M
66.72%
+102.20K
2024Q3
53
2.77M
66.42%
+227.70K
2024Q2
54
2.39M
67.77%
-279.08K
2024Q1
55
2.43M
68.82%
-232.89K
2023Q4
54
2.50M
71.18%
-175.24K
2023Q3
53
2.57M
73.29%
-212.86K
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Accelmed Growth Partners Management Ltd
1.44M
24.49%
--
--
Sep 04, 2025
22NW, LP
537.00K
9.12%
--
--
Sep 30, 2025
Nantahala Capital Management, LLC
403.92K
6.86%
--
--
Sep 30, 2025
Lincoln Alternative Strategies LLC
365.85K
6.21%
+365.85K
--
Sep 03, 2025
Renaissance Technologies LLC
101.53K
1.72%
+3.50K
+3.57%
Sep 30, 2025
Geode Capital Management, L.L.C.
18.14K
0.31%
-56.00
-0.31%
Sep 30, 2025
The Vanguard Group, Inc.
23.55K
0.4%
-61.09K
-72.18%
Sep 30, 2025
Susquehanna International Group, LLP
12.43K
0.21%
+12.43K
--
Sep 30, 2025
Rubinstein (Samuel)
10.77K
0.18%
-9.09K
-45.79%
Nov 18, 2025
Mehr Anzeigen

Verbundene ETFs

Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Anteil0%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Apr 26, 2024
Merger
10→1
Apr 26, 2024
Merger
10→1
Apr 26, 2024
Merger
10→1
Apr 26, 2024
Merger
10→1
Datum
Ex-Dividendentag
Art
Verhältnis
Apr 26, 2024
Merger
10→1
Apr 26, 2024
Merger
10→1
Apr 26, 2024
Merger
10→1
Apr 26, 2024
Merger
10→1
KeyAI